Abstract

Purpose

This study investigated whether Ki-67 labeling index (LI) correlated with clinical outcomes after SRS for atypical meningiomas.

Methods

This retrospective study examined 39 patients with atypical meningiomas who underwent SRS over a 10-year study period. Ki-67 LI was categorized into 3 groups: low (< 5%), intermediate (5%–10%), and high (> 10%). Local tumor control rates (LCRs), progression-free rates (PFRs), disease-specific survival (DSS) rates, and adverse radiation-induced events (AREs) were evaluated.

Results

The median follow-up periods were 26 months. SRS was performed at a median prescription dose of 18 Gy for tumors with a median Ki-67 LI of 9.6%. The 3-year LCRs were 100%, 74%, and 25% in the low, intermediate, and high LI groups, respectively (p = 0.011). The 3-year PFRs were 100%, 40%, and 0% in the low, intermediate, and high LI groups (p = 0.003). The 5-year DSS rates were 100%, 89%, and 50% in the low, intermediate, and high LI groups (p = 0.019). Multivariable Cox proportional hazard analysis showed a significant correlation of high LI with lower LCR (hazard ratio [HR], 3.92; 95% confidence interval [CI] 1.18–13.04, p = 0.026), lower PFR (HR 3.80; 95% CI 1.46–9.88, p = 0.006), and shorter DSS (HR 6.55; 95% CI 1.19–35.95, p = 0.031) compared with intermediate LI. The ARE rates were minimal (8%) in the entire group.

Conclusion

Patients with high Ki-67 LI showed significantly more tumor progression and tumor-related death. Ki-67 LI might offer valuable predictive insights for the post-SRS management of atypical meningiomas.

中文翻译：

---

Ki-67 标记指数可预测立体定向放射外科治疗后非典型脑膜瘤患者的肿瘤进展模式和生存率

摘要

目的

本研究调查了 Ki-67 标记指数 (LI) 是否与非典型脑膜瘤 SRS 后的临床结果相关。

方法

这项回顾性研究对 39 名非典型脑膜瘤患者进行了为期 10 年的研究，这些患者接受了 SRS 治疗。 Ki-67 LI 分为 3 组：低（< 5%）、中（5%–10%）和高（> 10%）。评估了局部肿瘤控制率（LCR）、无进展率（PFR）、疾病特异性生存率（DSS）和放射不良事件（ARE）。

结果

中位随访期为 26 个月。对于肿瘤，SRS 的中位处方剂量为 18 Gy，中位 Ki-67 LI 为 9.6%。低、中、高 LI 组的 3 年 LCR 分别为 100%、74% 和 25% ( p  = 0.011)。低、中、高 LI 组的 3 年 PFR 分别为 100%、40% 和 0% ( p  = 0.003)。低、中、高 LI 组的 5 年 DSS 率分别为 100%、89% 和 50% ( p  = 0.019)。多变量 Cox 比例风险分析显示，高 LI 与较低的 LCR（风险比 [HR]，3.92；95% 置信区间 [CI] 1.18–13.04，p  = 0.026）、较低的 PFR（HR 3.80；95% CI 1.46）存在显着相关性。 –9.88，p = 0.006）， 与中间 LI 相比， DSS 更短（HR 6.55；95% CI 1.19–35.95，p = 0.031）。整个组的 ARE 率最低（8%）。

结论

Ki-67 LI 高的患者表现出明显更多的肿瘤进展和肿瘤相关死亡。 Ki-67 LI 可能为非典型脑膜瘤的 SRS 治疗后管理提供有价值的预测见解。